JP2019509976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509976A5 JP2019509976A5 JP2018528648A JP2018528648A JP2019509976A5 JP 2019509976 A5 JP2019509976 A5 JP 2019509976A5 JP 2018528648 A JP2018528648 A JP 2018528648A JP 2018528648 A JP2018528648 A JP 2018528648A JP 2019509976 A5 JP2019509976 A5 JP 2019509976A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 129
- 238000000034 method Methods 0.000 claims description 21
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000013595 glycosylation Effects 0.000 claims description 5
- 238000006206 glycosylation reaction Methods 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000001215 fluorescent labelling Methods 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 210000003437 trachea Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021163120A JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262303P | 2015-12-02 | 2015-12-02 | |
| US62/262,303 | 2015-12-02 | ||
| PCT/US2016/064394 WO2017096026A1 (en) | 2015-12-02 | 2016-12-01 | Antibodies specific to glycosylated pd-1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163120A Division JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509976A JP2019509976A (ja) | 2019-04-11 |
| JP2019509976A5 true JP2019509976A5 (OSRAM) | 2020-01-16 |
| JP7003036B2 JP7003036B2 (ja) | 2022-02-04 |
Family
ID=58797717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528648A Active JP7003036B2 (ja) | 2015-12-02 | 2016-12-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
| JP2021163120A Active JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163120A Active JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10858432B2 (OSRAM) |
| EP (1) | EP3383412A4 (OSRAM) |
| JP (2) | JP7003036B2 (OSRAM) |
| KR (1) | KR102809728B1 (OSRAM) |
| CN (1) | CN109152798B (OSRAM) |
| WO (1) | WO2017096026A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| CN107949573B (zh) | 2015-09-01 | 2022-05-03 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN114773481B (zh) | 2015-10-02 | 2025-04-29 | 豪夫迈·罗氏有限公司 | 对pd1和tim3特异性的双特异性抗体 |
| EP3383412A4 (en) | 2015-12-02 | 2019-06-05 | Stcube, Inc. | SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF |
| JP7572146B2 (ja) * | 2016-03-29 | 2024-10-23 | エスティーキューブ アンド カンパニー，インコーポレイテッド | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
| EP3487883B1 (en) | 2016-07-20 | 2023-01-04 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| US20190343951A1 (en) * | 2017-01-13 | 2019-11-14 | National Research Council Of Canada | Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| FI3606955T3 (fi) | 2017-04-05 | 2025-01-08 | Hoffmann La Roche | Pd1:een ja lag3:een spesifisesti sitoutuvia bispesifisiä vasta-aineita |
| AU2018277545B2 (en) | 2017-05-31 | 2025-05-15 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 |
| US11542331B2 (en) | 2017-06-06 | 2023-01-03 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands |
| TWI708787B (zh) | 2018-03-02 | 2020-11-01 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及其用途 |
| US20210363255A1 (en) * | 2018-04-04 | 2021-11-25 | Truebinding, Inc. | Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides |
| EP4349411A3 (en) | 2018-06-20 | 2024-06-19 | Incyte Corporation | Anti-pd-1 antibodies and uses thereof |
| CN111166867B (zh) * | 2018-11-09 | 2022-12-20 | 中国科学院分子细胞科学卓越创新中心 | Pd-1泛素化激动剂的功能与用途 |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| JP7771749B2 (ja) | 2019-08-08 | 2025-11-18 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| WO2021062323A1 (en) * | 2019-09-26 | 2021-04-01 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| JP2022552282A (ja) | 2019-10-09 | 2022-12-15 | エスティーキューブ アンド カンパニー | グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法 |
| WO2022068919A1 (zh) * | 2020-09-30 | 2022-04-07 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
| US20240239892A1 (en) * | 2021-05-18 | 2024-07-18 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Anti-pd-1 polypeptides and their use |
| CN113372447A (zh) * | 2021-05-26 | 2021-09-10 | 重庆中元汇吉生物技术有限公司 | 抗pivka-ii单克隆抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| WO2004056875A1 (en) * | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| ES2427147T3 (es) | 2004-06-30 | 2013-10-29 | Mayo Foundation For Medical Education And Research | Anticuerpo sHlgM12 útil para tratar esclerosis múltiple |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| EP2418278A3 (en) * | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| US20110159023A1 (en) * | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| EP2542581A4 (en) | 2010-03-01 | 2014-01-22 | David Gladstone Inst | APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF |
| CN103906535B (zh) | 2011-08-15 | 2017-07-14 | 芝加哥大学 | 与葡萄球菌蛋白a的抗体相关的组合物和方法 |
| EP2755688A4 (en) | 2011-10-27 | 2014-08-06 | Nkt Therapeutics Inc | HUMANIZED ANTIBODIES AGAINST INKT |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CA2874117C (en) * | 2012-07-02 | 2021-10-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia |
| WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| RS63571B9 (sr) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva |
| AU2014339900B2 (en) | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| PL3081576T3 (pl) * | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| MY189089A (en) | 2013-12-17 | 2022-01-25 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN103897036B (zh) * | 2014-03-24 | 2016-02-24 | 郑州大学 | 一种pd-1蛋白胞外段亲和肽l8及其应用 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN114380909A (zh) | 2015-03-30 | 2022-04-22 | 斯特库比股份有限公司 | 特异性针对糖基化的pd-l1的抗体及其使用方法 |
| SG10201913304VA (en) | 2015-07-29 | 2020-03-30 | Sharp Kk | Method for device-to-device relay procedure |
| CN114773481B (zh) * | 2015-10-02 | 2025-04-29 | 豪夫迈·罗氏有限公司 | 对pd1和tim3特异性的双特异性抗体 |
| RU2746409C1 (ru) * | 2015-10-02 | 2021-04-13 | Ф. Хоффманн-Ля Рош Аг | Антитела к pd1 и способы их применения |
| EP3383412A4 (en) | 2015-12-02 | 2019-06-05 | Stcube, Inc. | SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF |
-
2016
- 2016-12-01 EP EP16871487.1A patent/EP3383412A4/en active Pending
- 2016-12-01 KR KR1020187018671A patent/KR102809728B1/ko active Active
- 2016-12-01 WO PCT/US2016/064394 patent/WO2017096026A1/en not_active Ceased
- 2016-12-01 JP JP2018528648A patent/JP7003036B2/ja active Active
- 2016-12-01 US US15/778,663 patent/US10858432B2/en active Active
- 2016-12-01 CN CN201680078477.9A patent/CN109152798B/zh active Active
-
2020
- 2020-11-13 US US17/097,892 patent/US11981736B2/en active Active
-
2021
- 2021-10-01 JP JP2021163120A patent/JP7455787B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509976A5 (OSRAM) | ||
| US12060423B2 (en) | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies | |
| US10081680B2 (en) | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies | |
| JP2019502405A5 (OSRAM) | ||
| CA3043691C (en) | Antibody binding specifically to cd66c and use thereof | |
| JP2019512210A5 (OSRAM) | ||
| KR20250169224A (ko) | 암의 치료를 위한 항체, 또는 그의 항원-결합 단편의 조합물 및 그의 조성물 | |
| JP2024542914A (ja) | ヒトｃｘｃｌ１６抗体およびその使用 | |
| JPWO2022217019A5 (OSRAM) | ||
| TW202336033A (zh) | 抗體之新穎組合及用途 | |
| CN120958025A (zh) | 针对含cub结构域的蛋白1(cdcp1)的抗体及其用途 | |
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела | |
| HK40040747A (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| JPWO2021072277A5 (OSRAM) | ||
| JPWO2022242680A5 (OSRAM) | ||
| HK1262017B (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| HK1262017A1 (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| EA049228B1 (ru) | Набор для диагностики или иммунотерапии заболевания, ассоциированного с cd47 |